Author: mercia1

Profile picture of mercia1
Website
http://www.mercia.co.uk

Posts by mercia1

PolyTherics receives milestone payment as Celtic Pharma progresses development of long-acting version of Blood Factor VIII produced using PolyTherics’ TheraPEG™ technology

Posted on

London, UK, 7 March 2013 – PolyTherics Limited (“PolyTherics”), a provider of solutions for the development of better biopharmaceuticals, announces that it has received an undisclosed milestone payment from Celtic Pharma Holdings (“Celtic”), the international healthcare group, triggered by further progress on their haematology alliance to produce longer-acting versions of blood factor proteins. In 2012

Mercia Fund Management launches Mercia Growth Fund 2 – a new hybrid EIS/SEIS investment opportunity

Posted on

Henley-in-Arden, 6 March 2013. Venture capital fund manager Mercia Fund Management has launched Mercia Growth Fund 2, its second hybrid EIS/SEIS fund. Mercia Growth Fund 2 offers the flexibility to invest either in EIS or SEIS, while enabling investors to maximise tax efficiency. Dr. Mark Payton, Managing Director of Mercia Fund Management commented on the

PsiOxus Therapeutics completes patient enrolment for Phase II wasting disease therapeutic MT-102

Posted on

First-in-Class Anabolic Catabolic Transforming Agent Holds Promise in Treating Cancer Cachexia, Age-Related Sarcopenia OXFORD, UK – March 4, 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia. The agent’s unique

Forward Group takes equity stake in Mercia Fund Management

Posted on

Henley in Arden, 18 February 2013. Venture capital fund manager Mercia Fund Management has today announced that Forward Group, an evergreen private equity fund, has become a shareholder. The move strengthens Mercia Fund Management’s position as a provider of venture capital and related services. Terms of the investment were not disclosed. Run by a team

DTRA awards US$3.3m contract to psioxus therapeutics to develop biodefence vaccine adjuvants

Posted on

OXFORD, UK – 16 January 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a US$3.3 million contract from the US Defense Threat Reduction Agency (DTRA) to develop biodefence vaccine adjuvants using the company’s proprietary PolyMAP technology to help improve the safety and efficacy of two vaccines candidates:

Mercia Fund Management announces over subscription to the SEIS portion of Mercia Growth Fund 1

Posted on

Mercia Growth Fund SEIS investment opportunity closed within three months Birmingham, 19 November 2012. Mercia Fund Management (MFM) today announced an over subscription to the SEIS portion of its Mercia Growth Fund, less than three months after the fund’s launch. The Mercia Growth Fund, a ‘hybrid’ fund offering both Seed EIS (SEIS) and later stage

Allinea MAPs Out New Performance Tool

Posted on

SALT LAKE CITY, Utah, 2012-11-12 – Allinea Software shifted the performance landscape at SC12 today with the announcement of a new performance analysis tool, Allinea MAP. Better known for their high-performance, scalable parallel debugger, Allinea DDT, the company has taken an unusual tack in developing the new product. “We worked with a range of leading

National newspapers cover Mercia SEIS Fund

Posted on

Mercia Fund Management has been in the spotlight in the UK press recently with articles in the Financial Times and The Sunday Times. In an article in The Sunday Times on 30 September 2012, “Spotlight on tax saving schemes”, Mercia Fund Management’s Growth Fund was highlighted as a good example for tax efficient saving. “Mercia

Mercia Fund Management highlights combined SEIS and EIS Funds at VCT and EIS Investor Forum

Posted on

Investors gain update on Venture Capital Trusts, Enterprise Investment Schemes and hybrid EIS/SEIS funds Birmingham, 6 November 2012. Mercia Fund Management (MFM) will be presenting its Mercia Growth Fund, a ‘hybrid’ fund offering combining separate Seed EIS (SEIS) and later stage EIS investments, at the VCT and EIS Investor Forum on 21 November 2012. Attended

UK Government Awards 1.7M Grant To Psioxus Therapeutics For Second Phase I/II Clinical Trial Of Cancer Vaccine

Posted on

FOR IMMEDIATE RELEASE‘OCTAVE’ Study Will AssessColoAd1in Patients with Ovarian Cancer OXFORD, UK – 31 October 2012– PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced the award of a £1.7 million ($2.7 million) grant from the UK government-backed Biomedical Catalyst to initiate a Phase I/II clinical trial to assess the use of ColoAd1